Cargando…

Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor

BACKGROUND: Malignant myofibroblastic tumors are a rare group of soft tissue sarcomas, for which a prognosis prediction model is lacking. Based on the Surveillance, Epidemiology, and End Results (SEER) database and cases from Nanjing Drum Tower Hospital, the current study constructed and validated a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaolu, Liu, Baorui, Li, Rutian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166985/
https://www.ncbi.nlm.nih.gov/pubmed/36951597
http://dx.doi.org/10.1002/cam4.5668
_version_ 1785038564831002624
author Wang, Xiaolu
Liu, Baorui
Li, Rutian
author_facet Wang, Xiaolu
Liu, Baorui
Li, Rutian
author_sort Wang, Xiaolu
collection PubMed
description BACKGROUND: Malignant myofibroblastic tumors are a rare group of soft tissue sarcomas, for which a prognosis prediction model is lacking. Based on the Surveillance, Epidemiology, and End Results (SEER) database and cases from Nanjing Drum Tower Hospital, the current study constructed and validated a nomogram to assess overall survival of patients with malignant myofibroblastic tumors. METHODS: Data of patients with myofibroblastic tumors diagnosed between 2000 and 2018 were extracted from the SEER database. Similarly, data of patients with myofibroblastic tumor in Nanjing Drum Tower Hospital between May 2016 and March 2022 were collected. Then, we conducted univariate and multivariate Cox analyses to identify independent prognostic parameters to develop the nomogram. The model was evaluated by concordance index (C‐index), calibration curve, the area under the curve (AUC), decision curve analysis (DCA), Kaplan–Meier analysis, and subgroup analyses. RESULTS: Seven variables were selected to construct the nomogram. The results of the C‐index (0.783), calibration curve, the AUCs, and subgroup analyses demonstrated the accurate predictive capacity and excellent discriminative ability of the nomogram. The DCA of the model indicated its better clinical net benefit than that of the traditional system. CONCLUSION: Evaluation of the predictive performance of the nomogram revealed the superior sensitivity and specificity of the model and the higher prediction accuracy of the outcomes compared with those of the traditional system. The established nomogram may assist patients in consultation and help physicians in clinical decision‐making.
format Online
Article
Text
id pubmed-10166985
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101669852023-05-10 Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor Wang, Xiaolu Liu, Baorui Li, Rutian Cancer Med RESEARCH ARTICLES BACKGROUND: Malignant myofibroblastic tumors are a rare group of soft tissue sarcomas, for which a prognosis prediction model is lacking. Based on the Surveillance, Epidemiology, and End Results (SEER) database and cases from Nanjing Drum Tower Hospital, the current study constructed and validated a nomogram to assess overall survival of patients with malignant myofibroblastic tumors. METHODS: Data of patients with myofibroblastic tumors diagnosed between 2000 and 2018 were extracted from the SEER database. Similarly, data of patients with myofibroblastic tumor in Nanjing Drum Tower Hospital between May 2016 and March 2022 were collected. Then, we conducted univariate and multivariate Cox analyses to identify independent prognostic parameters to develop the nomogram. The model was evaluated by concordance index (C‐index), calibration curve, the area under the curve (AUC), decision curve analysis (DCA), Kaplan–Meier analysis, and subgroup analyses. RESULTS: Seven variables were selected to construct the nomogram. The results of the C‐index (0.783), calibration curve, the AUCs, and subgroup analyses demonstrated the accurate predictive capacity and excellent discriminative ability of the nomogram. The DCA of the model indicated its better clinical net benefit than that of the traditional system. CONCLUSION: Evaluation of the predictive performance of the nomogram revealed the superior sensitivity and specificity of the model and the higher prediction accuracy of the outcomes compared with those of the traditional system. The established nomogram may assist patients in consultation and help physicians in clinical decision‐making. John Wiley and Sons Inc. 2023-03-23 /pmc/articles/PMC10166985/ /pubmed/36951597 http://dx.doi.org/10.1002/cam4.5668 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Wang, Xiaolu
Liu, Baorui
Li, Rutian
Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
title Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
title_full Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
title_fullStr Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
title_full_unstemmed Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
title_short Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
title_sort development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166985/
https://www.ncbi.nlm.nih.gov/pubmed/36951597
http://dx.doi.org/10.1002/cam4.5668
work_keys_str_mv AT wangxiaolu developmentandvalidationofanomogramforpredictingsurvivalinpatientswithmalignantmyofibroblastictumor
AT liubaorui developmentandvalidationofanomogramforpredictingsurvivalinpatientswithmalignantmyofibroblastictumor
AT lirutian developmentandvalidationofanomogramforpredictingsurvivalinpatientswithmalignantmyofibroblastictumor